Some answers, more questions for multi-cancer early detection tests

The PATHFINDER 2 and NHS-Galleri studies offer new insights into multi-cancer early detection tests. These researches provide complementary evidence regarding the clinical performance, safety, and implementation of such tests in practice. They focus on how well the tests work, whether they are safe for patients, and how they could be effectively utilized. However, they also underscore another significant challenge ahead. This challenge involves demonstrating the population-level benefit of these tests. This means it is necessary to determine if these tests genuinely improve the health and survival of people on a large scale. The article was published in Nature Medicine on September 22, 2026.